RNA Therapeutics: Delivery Problems and Solutions—A Review
Pharmaceutics · 07.10.2025 · 17 (10) · 1305
DOI: 10.3390/pharmaceutics17101305 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 07.10.2025. Verfasst von Natalia Pozdniakova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, 115522 Moscow, Russia. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 226 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Program for Basic Research in the Russian Federation for a long-term period (2021-2030).
Abstract (Originalsprache)
RNA-based therapeutics offer transformative potential for treating devastating diseases. However, current RNA delivery technologies face significant hurdles, including inefficient tissue targeting, insufficient selectivity, and severe side effects, leading to the termination of many clinical trials. This review critically assesses the landscape of RNA-derived medicines, examining world-renowned mRNA vaccines (Spikevax, BNT162b2/Comirnaty) and RNA-based therapeutics like Miravirsen (anti-miR-122). It details the composition and clinical trial results of numerous modified short RNA drugs (e.g., siRNAs, miRNA mimetics/inhibitors) targeting various conditions. Prospects for RNA-based medicines are analysed for diseases with substantial societal impact, such as cancer, autoimmune disorders, and infectious diseases, with a focus on evolving delivery methods, including lipid nanoparticles, viral vectors, and exosomes. RNA-mediated macrophage reprogramming emerges as a promising strategy, potentially enhancing both delivery and clinical efficacy. This review highlights that while approved RNA therapies primarily target rare diseases due to delivery limitations, novel approaches in RNA modification, targeted delivery systems, and enhanced understanding of molecular mechanisms are crucial for expanding their application to prevalent diseases and unlocking their full therapeutic potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, 115522 Moscow, Russia.
- Faculty of Physics, Lomonosov Moscow State University, 119991 Moscow, Russia.
- Vavilov Institute of General Genetics of Russian Academy of Sciences, 119991 Moscow, Russia.
- Institute of Biomedical Chemistry of Russian Academy of Sciences, 119121 Moscow, Russia.
ORCID-Profile: Natalia Pozdniakova, Evgenii Generalov, Olga Tarasova
Förderung
- Program for Basic Research in the Russian Federation for a long-term period (2021-2030)
Zitieren
APA
Pozdniakova, N., Generalov, E., Shevelev, A., & Tarasova, O. (2025). RNA Therapeutics: Delivery Problems and Solutions—A Review. Pharmaceutics, 17(10), 1305. https://doi.org/10.3390/pharmaceutics17101305
Vancouver
Pozdniakova N, Generalov E, Shevelev A, Tarasova O. RNA Therapeutics: Delivery Problems and Solutions—A Review. Pharmaceutics. 2025;17(10):1305. doi:10.3390/pharmaceutics17101305
BibTeX
@article{Pozdniakova2025,
author = {Pozdniakova, Natalia and Generalov, Evgenii and Shevelev, Alexei and Tarasova, Olga},
title = {RNA Therapeutics: Delivery Problems and Solutions—A Review},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {10},
pages = {1305},
doi = {10.3390/pharmaceutics17101305}
}
EUVIMED